Identification of genetic modifiers for PC and melanoma risk in p16-Leiden carriers could possibly explain the variability of cancer occurrence within p16-Leiden positive families and ultimately favor individualized surveillance and clinical management of those patients [4, 12]. Here, CDKN2A is linked to cancer.